- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02742064
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression
July 16, 2018 updated by: Cogito Health Inc
The purpose of this study is to determine if a mobile sensing platform can passively and objectively detect the presence of clinically significant mood disorder symptomatology and symptom progression over time.
Meeting this goal will allow for improved risk categorization, prediction of relapse, and measurement of disease progression in a lifetime prevalence population.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
899
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Participants will be selected from the MoodNetwork, an online network of individuals with mood disorders, which is hosted by MGH.
A subset of participants with mood disorders enrolled in MoodNetwork will download Cogito's mobile sensing platform on their mobile phones.
Description
Inclusion Criteria:
- Age 18 or older
- Have a smartphone and cell service plan, including voice and data, that meets the device requirements of the Mobile Sensing Platform.
- Enrolled in the MoodNetwork
Exclusion Criteria:
- Report positively on the QIDS-SR suicide item during study intake
- Total score greater than 15 on the QIDS-SR during the screening process
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
MDD-Single Episode
1. Subjects who have experienced 1 episode of major depressive disorder (MDD) in their lifetime.
|
Other Names:
|
MDD-Recurrent
1. Subjects who have experienced 2 or more episodes of depressive disorder (MDD) in their lifetime.
|
Other Names:
|
Bipolar Disorder
1. Subjects who have been diagnosed with bipolar disorder in their lifetime.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Severity of MDD symptoms as assessed by QIDS SR
Time Frame: 6 months
|
6 months
|
Severity of Mania symptoms as assessed by ASRM
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
December 31, 2017
Study Completion (Actual)
March 31, 2018
Study Registration Dates
First Submitted
April 11, 2016
First Submitted That Met QC Criteria
April 13, 2016
First Posted (Estimate)
April 18, 2016
Study Record Updates
Last Update Posted (Actual)
July 17, 2018
Last Update Submitted That Met QC Criteria
July 16, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R44MH107065-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Charite University, Berlin, GermanyCompletedTreatment Resistant Depression | Depression, Unipolar | Depression ChronicGermany
Clinical Trials on Cogito Companion Mobile Phone Application
-
Cogito Health IncNational Institute of Mental Health (NIMH); Brigham and Women's Hospital; Partners...CompletedBehavioral Health With Medical ComorbiditiesUnited States
-
VA Eastern Colorado Health Care SystemCompletedFeasibility | Mobile Applications | Mental Health Issue | Acceptability of Health Care | Cell Phone UseUnited States
-
VA Eastern Colorado Health Care SystemUniversity of Colorado, Denver; Military Suicide Research ConsortiumCompletedPsychological DistressUnited States
-
University Hospitals Cleveland Medical CenterCompleted
-
Northwestern UniversityNational Institute of Mental Health (NIMH)WithdrawnDepressive Symptoms | Anxiety GeneralizedUnited States
-
MelanomaPRO, RussiaPrivolzhsky Research Medical UniversityRecruitingNevus | Nevus, Pigmented | Melanoma (Skin) | Basal Cell Carcinoma | Squamous Cell Carcinoma | Bowen's Disease | Nevus, Spitz | Melanoma in Situ | Nevus Halo | Spot PigmentedRussian Federation
-
Anjali Raja BeharelleMediService AGEnrolling by invitationHypertension | Medication AdherenceSwitzerland
-
Collabree AGUniversity Hospital, Basel, SwitzerlandRecruitingHypertension | Medication AdherenceSwitzerland
-
General Health Council, MexicoEli Lilly and Company; Instituto de Seguridad y Servicios Sociales de los Trabajadores...RecruitingDiabetes Mellitus, Type 2Mexico
-
Chulalongkorn UniversityThai Red Cross AIDS Research Centre; International AIDS SocietyCompletedHIV Prevention | Adherence, Medication | Adolescent Behavior | Mobile Health | Sexual HealthThailand